Canaccord Analyst Upgrades AngioDynamics, Raises PT To $20
Canaccord analyst Jason Mills today upgraded his rating on AngioDynamics Inc. (ANGO) to Buy from Hold, and raised his price target to $20 from $16.25.
“It is our view that ANGO common at current levels not only fails to reflect this viable growth and improved cash flow potential but represents an attractive risk/reward bet in the small-cap med-tech value sphere”, Mills wrote.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Jason Mills currently has a one-year average return of -2.7% and a 41% success rate. He is ranked #2853 out of 3115 analysts.